Press Release
New clinical research entity formed in a three-company merger.
Introducing Josh Stent, CEO at Momentum Clinical Research - the first and largest network of clinical trial sites across New Zealand and Australia. In a recent media release, Josh emphasised how Momentum operates as a one stop solution for research organisations and biotech companies looking to host clinical trials across both Australia and New Zealand. With sites that have been operating for over 20 years, Momentum Clinical Research can facilitate a vast variety of therapeutic clinical trials from healthy volunteer studies including vaccinations, to studies of general medical conditions, chronic pain and specialised areas, such as obesity, dermatology and HIV.
March 01, 2024
•3 minutes
New entity formed
New Zealand’s P3 Research and Australia’s AusTrials and Holdsworth House have announced a merger to form Momentum Clinical Research, an extensive clinical research entity with sites that have been operating for more than 20 years.
The new multi-site entity can facilitate a variety of therapeutic clinical trials, from healthy volunteer studies including vaccinations to studies of general medical conditions, chronic pain and specialised areas, such as obesity, dermatology and HIV.
Momentum Clinical Research CEO Joshua Stent said the entity works as a one-stop solution for research organisations and biotech companies looking to host clinical trials in Australia and New Zealand.
P3 Research Managing Director Prof. Richard Stubbs said Momentum Clinical Research’s facilities are equipped to host a diverse range of studies throughout their different phases, with further plans for expansion to meet the demand of both local and international trials.
“Our study coordinators are fully trained with a current GCP certification and are proficient in all the leading electronic case report form and randomisation platforms. Additionally, some coordinators have completed further certifications with the International Air Transport Association on the shipment of dangerous goods,”
“Our study coordinators are fully trained with a current GCP certification and are proficient in all the leading electronic case report form and randomisation platforms. Additionally, some coordinators have completed further certifications with the International Air Transport Association on the shipment of dangerous goods,”
Josh Stent
Connect with us
If you are keen to explore how Momentum can help you with your next clinical trial, them please reach out to us here.
Contact